NCT06692153撤回不适用
A Multicenter, Pivotal, Randomized Controlled Trial Comparing the Safety and Efficacy of an Automated Insulin Delivery System With the Standard of Care in Adults With Type 2 Diabetes (EMBRACE-T2D)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 入组人数
- 360
- 试验地点
- 18
- 主要终点
- HbA1c change
研究概览
简要总结
This is a multi-center, randomized control study that will evaluate the safety and effectiveness of the embecta Automated Insulin Delivery System in adults with Type 2 diabetes requiring insulin therapy
详细描述
This outpatient study consists of 2 phases.
Phase 1 (Single Arm) will establish the initial safety of the embecta AID system prior to initiating the phase 2 (RCT). Participants will follow the same protocol as the RCT AID group. During the treatment period all participants will undergo supervised exercise and meal challenges.
Phase 2 (Randomized Control Trial (RCT)) will be a 13-week parallel group RCT to evaluate the safety and efficacy with a 2:1 randomization to intervention with AID versus standard of care (SC) insulin therapy. The RCT AID group will use the embeca AID with Tidepool Loop app as well as the Dexcom G6 continuous glucose monitor (CGM).
Participants in both phases will do in-clinic or virtual visits at least monthly for a total of 9 visits. During the treatment period all participants will undergo supervised exercise and meal challenges.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sufficient cognitive ability, per investigator judgment, to provide informed consent for study participation on an IRB approved consent form
- •≥18 years of age at time of consent
- •Diagnosis of T2D, per investigator judgment, of at least 6 months duration prior to time of screening. Any permissible diabetes medications, including insulin, to the exclusion sulfonylurea, meglitinide, or repaglinides have been relatively stable for the past 30 days.
- •Currently treated with (1) multiple daily injections of insulin (MDI; defined as using basal insulin and at least one daily prandial injection), (2) an insulin pump without automation or (3) basal insulin without prandial insulin provided that screening HbA1c ≥7.5% (basal-only) for ≥3 months at the time of screening (per participant report and medical records available at the site)
- •Either not using any noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that can have a meaningful effect on glucose levels, or if using, then the dose has been stable for at least 4 weeks prior to screening based on investigator discretion
- •Willing to use U-100 (i.e., insulin lispro or insulin aspart) while using the embecta AID system if assigned to the AID group
- •Willing to not use concentrated insulin above U-100 or inhaled insulin while using the embecta AID system
- •Willing to participate in the study meal and exercise challenges if assigned to AID use in either the Single Arm Phase or the RCT AID group, and have a care partner, trained in hypoglycemia treatment guidelines including glucagon use, present during and immediately after the exercise challenges unless exercise challenges will be done in clinic.
- •Total daily insulin dose (TDD) <300 units/day
- •HbA1c ≤ 11% based on point-of-care or local lab measurement at screening
- •Willing to comply with study procedures, regardless of study arm
- •Able to read and understand English (due to user interface and IFU only being available in English)
- •Willing to have primary care provider and/or primary endocrinologist notified of participation in the trial
- •Investigator believes that the participant can successfully and safely operate all study devices and is capable of adhering to the protocol and completing the study
- •No medical, psychiatric, or other conditions, or medications being taken that in the investigator's judgement would be a safety concern for participation in the study. This includes considering the potential impact of medical conditions known to be present including cardiovascular, liver, kidney disease, thyroid disease, adrenal disease, malignancies, vision difficulties, active proliferative retinopathy, or other medical conditions; psychiatric conditions including eating disorders; drug or alcohol abuse
- •Participant is not capable of becoming pregnant, or if they are capable, they must meet one of the following criteria:
- •a. has a negative urine pregnancy test and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the trial from screening until last follow-up visit. The following contraceptive measures are considered adequate: i. Combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal).
- •ii. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable).
- •iii. Placement of an intrauterine device or intrauterine hormone- releasing system.
- •iv. Barrier methods of contraception (condom or occlusive cap with spermicidal foam/gel/film/cream/suppository).
- •v. Has a vasectomized or sterile partner (where partner is sole partner of participant) and where vasectomy has been confirmed by medical assessment.
- •vi. Exercises true sexual abstinence. Sexual abstinence is defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
- •or b. Participant is of non-childbearing potential due to menopause with at least one year since last menses or a medical condition confirmed by the investigator
排除标准
- •Use of an AID system within the last 3 months prior to screening
- •Use of systemic glucocorticoids within the last 8 weeks prior to screening or anticipated use of systemic glucocorticoids during the study (topical or inhaled or local injection into spine/joint -i.e., non-systemic is acceptable)
- •Current use of sulfonylurea, meglitinide, or repaglinides medications (within 30 days prior to screening)
- •Current use of hydroxyurea (within 1 day prior to screening) as hydroxyurea is known to cause falsely high CGM values which could lead to incorrect dosing from the AID system.
- •Has had more than 2 severe hypoglycemic events requiring third party help or hospitalization within the last 6 months prior to screening
- •Lack of reliable telephone service (for contact) or internet (smartphone containing the closed-loop algorithm application)
- •Planned surgery or hospitalization for which use of the embecta AID system would need to be discontinued for more than 7 days
- •Known allergy to medical grade adhesives that precludes use of the embecta AID system or CGM
- •Skin condition at the site(s) that may be used for application of the study CGM or embecta AID system that precludes use of the AID system or CGM
- •Dialysis planned or anticipated for chronic kidney disease in the next 4 months
- •Pregnant (positive urine hCG), breast feeding, plan to become pregnant in the next 2 months, or sexually active without use of contraception.
- •Current participation in another diabetes or obesity-related interventional clinical trial.
- •Anticipated change of residency or travel for more than 7 days at a time during the study that may, per investigator judgment, interfere with the completion of study visits, contacts, or procedures.
- •Immediate family member (spouse, biological or legal guardian, child, sibling, parent) of, or someone who is, an investigative site personnel directly affiliated with this study or who is an employee of embecta, Tidepool or the JAEB Center for Health Research.
结局指标
主要结局
HbA1c change
时间窗: 13 weeks
The change in HbA1c at 13 weeks from baseline
次要结局
- CGM-measured time in range 70-180 mg/dL(13 weeks)
- CGM-measured time in tight range 70-140 mg/dL(13 weeks)
- CGM-measured time less than 54 mg/dL (non-inferiority, margin 0.5%)(13 weeks)
- CGM-measured time less than 70 mg/dL (non-inferiority, margin 0.5%)(13 weeks)
- CGM-measured mean glucose(13 weeks)
- CGM-measured time greater than 180 mg/dL(13 weeks)
- CGM-measured time greater than 250 mg/dL(13 weeks)
- CGM-measured time less than 70 mg/dL(13 weeks)
- CGM-measured time less than 54 mg/dL(13 weeks)
研究者
研究点 (18)
Loading locations...
相似试验
进行中（未招募）
不适用
BioGlue as an Adjunct for Structural Repair and Hemostasis in Chinese Acute Type A Aortic Dissections PatientsType A Aortic DissectionNCT03369977CryoLife, Inc.202
已完成
不适用
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AMNon-infected Diabetic Foot UlcerDiabetic WoundNon-ischemic Diabetic Foot UlcerDiabetic FootDiabetic Foot UlcerNCT06565156BioStem Technologies72
已完成
不适用
A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-ACDiabetic Foot UlcerNCT06511596BioStem Technologies71
招募中
不适用
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal ArteriesStenosisDissectionPeripheral Arterial DiseaseNCT06539689FrontAce Scientific Co., Ltd240
招募中
不适用
Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation LesionsCoronary Bifurcation LesionNCT06618248Dongguan TT Medical280